Quick Answer
Cytosorbents Corp reported Diluted EPS of $0.13 per share (loss) for fiscal year 2025.
Cytosorbents Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.13 | +65.8% |
| 2024 | -$0.38 | +41.5% |
| 2023 | -$0.65 | +13.3% |
| 2022 | -$0.75 | -31.6% |
| 2021 | -$0.57 | -185.0% |
| 2020 | -$0.20 | +66.7% |
| 2019 | -$0.60 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.05 | +0.0% | -266.7% |
| June 30, 2025 | $0.03 | +137.5% | +250.0% |
| March 31, 2025 | -$0.02 | +81.8% | +60.0% |
| September 30, 2024 | -$0.05 | +76.2% | +37.5% |
| June 30, 2024 | -$0.08 | +42.9% | +27.3% |
| March 31, 2024 | -$0.11 | +35.3% | +47.6% |
| September 30, 2023 | -$0.21 | +25.0% | -50.0% |
| June 30, 2023 | -$0.14 | +44.0% | +17.6% |
- Cytosorbents Corp showed an increase of +65.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Cytosorbents Corp’s diluted eps has grown by 78.3% (from $0.60 per share (loss) to $0.13 per share (loss)).
- The most recent figure is from Cytosorbents Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: